miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer

Breast Cancer Research and Treatment

Volumn 151, Issue 2, 2015, Pages 269-280

  Hu, Yunhui ^a   Xu, Kun ^b   Yagüe, Ernesto ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Doxorubicin; Drug resistance; miR 218; Survivin; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, HUMAN; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; MICRORNA; MIRN218 MICRORNA, HUMAN; PACLITAXEL; TRANSCRIPTOME;

ANIMAL; APOPTOSIS; BINDING SITE; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICRORNAS; PACLITAXEL; RNA, MESSENGER; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937764481     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3372-9     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138
2. Gu J, Fang X, Hao J, Sha X (2015) Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Biomaterials 45:99–114. doi:10.1016/j.biomaterials.2014.12.030
3. Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D, Al-Daccak R, Aoudjit F (2012) Alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 287(21):17065–17076. doi:10.1074/jbc.M112.349365
4. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71(5):1858–1870. doi:10.1158/0008-5472.CAN-10-3604
5. Korner C, Keklikoglou I, Bender C, Worner A, Munstermann E, Wiemann S (2013) MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem 288(12):8750–8761. doi:10.1074/jbc.M112.414128
6. Yahya SM, Elsayed GH (2014) A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem. doi:10.1016/j.clinbiochem.2014.12.013
7. Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223(2):102–115. doi:10.1002/path.2806
8. Greve TS, Judson RL, Blelloch R (2013) microRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol 29:213–239. doi:10.1146/annurev-cellbio-101512-122343
9. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E (2011) Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17(22):7105–7115
10. Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL (2013) MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 12:23. doi:10.1186/1476-4598-12-23
11. Chen DQ, Pan BZ, Huang JY, Zhang K, Cui SY, De W, Wang R, Chen LB (2014) HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget 5(10):3333–3349
12. He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ, Yu J (2012) MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med 18:1491–1498. doi:10.2119/molmed.2012.00304
13. Li J, Ping Z, Ning H (2012) miR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci 13(12):16053–16064. doi:10.3390/ijms131216053
14. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K, Inazawa J (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71(17):5765–5778. doi:10.1158/0008-5472.CAN-11-0368
15. Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL (2014) Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol 20(22):6906–6911. doi:10.3748/wjg.v20.i22.6906
16. Li Q, Zhu F, Chen P (2012) miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun 424(1):28–33. doi:10.1016/j.bbrc.2012.06.028
17. He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X (2014) miR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol. doi:10.1007/s13277-014-2814-z
18. Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, Cazzanelli G, Zhou Y, Patel N, Coombes C, Yague E (2013) Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol 85(2):186–196. doi:10.1016/j.bcp.2012.10.020
19. Zhou Y, Hu Y, Yang M, Jat P, Li K, Lombardo Y, Xiong D, Coombes RC, Raguz S, Yague E (2014) The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death Differ 21(3):462–474. doi:10.1038/cdd.2013.167
20. Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y, Zhang Y, Yague E, Xiong D (2014) Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat 143(2):287–299. doi:10.1007/s10549-013-2809-2
21. Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng T, Yang M, Xiong D (2013) Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 72(4):789–798
22. Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW, Liu FF (2015) The microRNA-218~survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget 6(2):1090–1100
23. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O’Sullivan B, Liu FF (2011) miR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71(6):2381–2391. doi:10.1158/0008-5472.CAN-10-2754
24. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22(11):2729–2740. doi:10.1093/emboj/cdg263
25. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(33):34087–34090. doi:10.1074/jbc.C400236200
26. Wang S, Huang X, Lee CK, Liu B (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29(29):4225–4236. doi:10.1038/onc.2010.180
27. Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Res Updat 5(2):65–72
28. Pennati M, Folini M, Zaffaroni N (2008) Targeting survivin in cancer therapy. Exp Opin Ther Targets 12(4):463–476. doi:10.1517/14728222.12.4.463
29. Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. Am Soc Hematol Edu Prog 2010:135–143. doi:10.1182/asheducation-2010.1.135
30. Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K (2011) Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urologic oncology 29(5):502–507. doi:10.1016/j.urolonc.2009.09.001
31. Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278(25):23130–23140. doi:10.1074/jbc.M300957200
32. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897–29903. doi:10.1074/jbc.M804612200
33. Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D (2013) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434(3):688–694. doi:10.1016/j.bbrc.2013.04.010
34. Liang Z, Li Y, Huang K, Wagar N, Shim H (2011) Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28(12):3091–3100. doi:10.1007/s11095-011-0570-y
35. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P (2014) Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28(1):118–128. doi:10.1038/leu.2013.125
36. Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma YL, Ji ZW, Li XX, Han K, Gao J, Qiu XC, Fan QY, Yang TT, Ma BA (2012) miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28(5):1764–1770. doi:10.3892/or.2012.1995
37. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27(18):2575–2582. doi:10.1038/sj.onc.1210919
38. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11(3):R27. doi:10.1186/bcr2257
39. Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, Cui SZ, Wang LT (2014) MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol 20(32):11347–11355. doi:10.3748/wjg.v20.i32.11347
40. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711):580–584. doi:10.1038/25141
41. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1):61–70. doi:10.1038/nrc2293
42. Kanwar JR, Kamalapuram SK, Kanwar RK (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 33(4):765–789. doi:10.1002/med.21264
43. Singh N, Krishnakumar S, Kanwar RK, Cheung CH, Kanwar JR (2014) Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today. doi:10.1016/j.drudis.2014.11.013
44. Nabilsi NH, Broaddus RR, Loose DS (2009) DNA methylation inhibits p53-mediated survivin repression. Oncogene 28(19):2046–2050. doi:10.1038/onc.2009.62
45. Huang J, Lyu H, Wang J, Liu B (2015) MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res 5(1):20–31
46. Wu DW, Cheng YW, Wang J, Chen CY, Lee H (2010) Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 70(24):10392–10401. doi:10.1158/0008-5472.CAN-10-2341
47. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67(17):8014–8021. doi:10.1158/0008-5472.CAN-07-1343
48. Holmes D (2012) Cancer drug’s survivin suppression called into question. Nat Med 18(6):842–843. doi:10.1038/nm0612-842b
49. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36 (Database issue):D149–153. doi:10.1093/nar/gkm995